https://www.pharmaradar360.com/article/what-to-know-about-the-new-wave-of-biotech-beauty-0686b992c03a8b71Pharma Surgeen2026-08-04T10:05:25.000ZWhat to Know About the New Wave of Biotech Beautyhttps://www.pharmaradar360.com/article/addressing-china-s-rise-in-biotech-by-removing-barriers-q-a-with-john-stanford-338ef1cadbf57c0cPharma Surgeen2026-08-04T10:03:21.000ZAddressing China’s Rise in Biotech by Removing Barriers: Q&A with John Stanfordhttps://www.pharmaradar360.com/article/seventh-meeting-of-the-subsidiary-body-on-implementation-sbi-7-digital-sequence-0a8debc65bf10547Pharma Surgeen2026-08-04T10:00:04.000ZSeventh meeting of the Subsidiary Body on Implementation (SBI-7): Digital sequence information on genetic resourceshttps://www.pharmaradar360.com/article/danske-bank-sees-zealand-pharma-as-potential-big-pharma-takeover-target-8a8bf26f03e07c8cPharma Surgeen2026-08-04T09:59:30.000ZDanske Bank sees Zealand Pharma as potential "big pharma" takeover targethttps://www.pharmaradar360.com/article/biotech-investors-are-waiting-for-the-wrong-milestone-in-ai-drug-discovery-c59b1ef9a5ac3eb5Pharma Surgeen2026-08-04T09:24:00.000ZBiotech Investors Are Waiting For The Wrong Milestone In AI Drug Discoveryhttps://www.pharmaradar360.com/article/icymi-fda-clears-medicus-to-begin-gorlin-syndrome-skinject-trial-6f62f0743b8873c0Pharma Surgeen2026-08-04T09:22:30.000ZICYMI: FDA Clears Medicus to Begin Gorlin Syndrome SkinJect Trialhttps://www.pharmaradar360.com/article/eli-lilly-retatrutide-early-access-opens-to-a-small-group-of-patients-before-fda-4a8a0f6f236d225cPharma Surgeen2026-08-04T09:13:39.000ZEli Lilly Retatrutide Early Access Opens to a Small Group of Patients Before FDA Approvalhttps://www.pharmaradar360.com/article/digital-health-firm-launches-integrated-glp-1-program-810e6ed260dbebdcPharma Surgeen2026-08-04T09:11:15.000ZDigital Health Firm Launches Integrated GLP-1 Programhttps://www.pharmaradar360.com/article/where-ai-fits-in-the-future-of-drug-development-22862ec014b32c3fPharma Surgeen2026-08-04T09:10:40.000ZWhere AI Fits in the Future of Drug Developmenthttps://www.pharmaradar360.com/article/amgen-contends-with-data-breach-exposing-patient-information-d6db659defb2d7c3Pharma Surgeen2026-08-04T08:48:45.000ZAmgen contends with data breach, exposing patient informationhttps://www.pharmaradar360.com/article/astrazeneca-shares-slump-after-400bn-bms-merger-rumours-71cf1f553cc60264Pharma Surgeen2026-08-04T08:48:45.000ZAstraZeneca shares slump after $400bn BMS merger rumourshttps://www.pharmaradar360.com/article/wuxi-apptec-s-support-for-small-and-emerging-biotech-companies-three-global-exam-511e65790230ab9cPharma Surgeen2026-08-04T08:45:00.000ZWuXi AppTec' s Support for Small and Emerging Biotech Companies: Three Global Exampleshttps://www.pharmaradar360.com/article/fda-peptide-vote-explained-why-these-drugs-are-not-approved-yet-79e63991479fd451Pharma Surgeen2026-08-04T08:32:27.000ZFDA peptide vote explained: Why these drugs are not approved yethttps://www.pharmaradar360.com/article/pharmaceutical-care-group-affordability-for-prescription-drugs-requires-examinat-3bb6956da548b955Pharma Surgeen2026-08-04T08:00:00.000ZPharmaceutical care group: Affordability for prescription drugs requires examination of the entire supply chainhttps://www.pharmaradar360.com/article/biotech-cbd-gummies-a-balanced-look-at-gummies-with-cannabidiol-view-lzhhilm6m-c907dc0bbd403a2bPharma Surgeen2026-08-04T07:57:21.000ZBiotech CBD Gummies: A Balanced Look at Gummies with Cannabidiol - View LzhhILM6mhttps://www.pharmaradar360.com/article/amsilk-collaboration-biotech-silk-protein-yarns-feature-in-balenciaga-55th-coutu-4cee326b299f9142Pharma Surgeen2026-08-04T07:30:00.000ZAMSilk collaboration: Biotech silk protein yarns feature in Balenciaga 55th Couture Collectionhttps://www.pharmaradar360.com/article/potential-astrazeneca-bristol-myers-mega-merger-could-trigger-new-m-a-wave-baaa266ed97d1746Pharma Surgeen2026-08-04T07:20:38.000ZPotential AstraZeneca-Bristol Myers mega-merger could trigger new M&A wavehttps://www.pharmaradar360.com/article/fda-approves-long-lasting-otc-pain-reliever-combining-acetaminophen-and-naproxen-b705877d8a45bc85Pharma Surgeen2026-08-04T07:19:42.000ZFDA approves long-lasting OTC pain reliever combining acetaminophen and naproxenhttps://www.pharmaradar360.com/article/stephanie-lueras-why-do-pharmaceutical-commercials-have-such-long-warning-lists-feede09ed38e1b21Pharma Surgeen2026-08-04T07:15:00.000ZStephanie Lueras: Why do pharmaceutical commercials have such long warning lists?https://www.pharmaradar360.com/article/price-to-sales-forward-of-shenyang-xingqi-pharmaceutical-co-ltd-class-a-szse-300-eaaf695635d81c9dPharma Surgeen2026-08-04T07:05:20.000ZPrice to sales forward of Shenyang Xingqi Pharmaceutical Co., Ltd. Class A – SZSE:300573https://www.pharmaradar360.com/article/la-aemps-informa-sobre-el-uso-correcto-de-los-desinfectantes-de-piel-sana-63f180a51e53e52bPharma Surgeen2026-08-04T07:00:51.000ZLa AEMPS informa sobre el uso correcto de los desinfectantes de piel sanahttps://www.pharmaradar360.com/article/former-novo-nordisk-north-america-executive-joins-board-of-us-biotech-company-65e268eb70e03273Pharma Surgeen2026-08-04T06:55:45.000ZFormer Novo Nordisk North America executive joins board of US biotech companyhttps://www.pharmaradar360.com/article/clinical-trials-sellas-life-sciences-09006b8e86504c0bPharma Surgeen2026-08-04T06:43:57.000ZClinical Trials - Sellas Life Scienceshttps://www.pharmaradar360.com/article/opus-genetics-completes-enrollment-in-opgx-lca5-phase-3-trial-cbeeec92db860353Pharma Surgeen2026-08-04T06:38:44.000ZOpus Genetics Completes Enrollment in OPGx-LCA5 Phase 3 Trialhttps://www.pharmaradar360.com/article/nurix-starts-phase-3-trial-of-bexobrutideg-against-pirtobrutinib-in-cll-ee7981e5aeaf0b96Pharma Surgeen2026-08-04T06:33:26.000ZNurix Starts Phase 3 Trial of Bexobrutideg Against Pirtobrutinib in CLLhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-ch-biotech-r-d-co-ltd-twse-6534-517b6aad6cc9abb4Pharma Surgeen2026-08-04T06:29:45.000ZPrice to earnings forward of CH Biotech R&D Co., Ltd. – TWSE:6534https://www.pharmaradar360.com/article/which-hotels-follow-fssai-rules-maharashtra-fda-has-no-official-list-71971379ebdc02d4Pharma Surgeen2026-08-04T06:26:00.000ZWhich hotels follow FSSAI rules? Maharashtra FDA has no official listhttps://www.pharmaradar360.com/article/announcement-of-partnership-with-the-japan-basketball-association-jba-65999e5dbe1c620aPharma Surgeen2026-08-04T06:01:34.000ZAnnouncement of Partnership with the Japan Basketball Association (JBA)https://www.pharmaradar360.com/article/sumitomo-pharma-contributes-to-relief-efforts-for-the-2026-kumamoto-earthquake-b097ac38bebdfe05Pharma Surgeen2026-08-04T06:00:00.000ZSumitomo Pharma Contributes to Relief Efforts for the 2026 Kumamoto Earthquakehttps://www.pharmaradar360.com/article/25-transfers-in-20-years-who-is-ias-tukaram-mundhe-why-his-fda-crackdown-reached-bc1e9433e391b491Pharma Surgeen2026-08-04T05:57:59.000Z25 Transfers in 20 Years: Who is IAS Tukaram Mundhe, why his FDA crackdown reached Bombay High Court?https://www.pharmaradar360.com/article/pharmaceutical-giants-astrazeneca-and-bristol-myers-squibb-are-in-merger-talks-c-0009f1e915d58d59Pharma Surgeen2026-08-04T05:50:57.000ZPharmaceutical giants AstraZeneca and Bristol-Myers Squibb are in merger talks; combined market value could exceed 2.7 trillion yuan - ChemNethttps://www.pharmaradar360.com/article/beyond-the-law-fda-oversight-and-grow-consumer-upgrade-skills-safety-f8d1a397e594bed7Pharma Surgeen2026-08-04T05:33:21.000ZBeyond the Law: FDA Oversight and Grow Consumer Upgrade-skills Safetyhttps://www.pharmaradar360.com/article/more-biotech-m-a-is-coming-whether-an-astrazeneca-bristol-myers-deal-happens-or-a6bd6670e70b54a0Pharma Surgeen2026-08-04T05:30:00.000ZMore Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Nothttps://www.pharmaradar360.com/article/india-pharma-sector-to-miss-2030-sales-target-amid-tariff-and-shipping-woes-trad-556010eeca1bbe5dPharma Surgeen2026-08-04T05:30:00.000ZIndia pharma sector to miss 2030 sales target amid tariff and shipping woes, trade body sayshttps://www.pharmaradar360.com/article/nurix-enrolls-first-patient-in-phase-3-trial-for-cll-drug-6da672a3d1c1d534Pharma Surgeen2026-08-04T05:12:46.000ZNurix enrolls first patient in phase 3 trial for CLL drughttps://www.pharmaradar360.com/article/nurix-therapeutics-announces-first-patient-enrolled-in-phase-3-daybreak-cll-306-be464a98cd5566dcPharma Surgeen2026-08-04T05:10:00.000ZNurix Therapeutics Announces First Patient Enrolled in Phase 3 DAYBreak CLL-306 Study of Bexobrutideg in Relapsed/Refractory CLL/SLLhttps://www.pharmaradar360.com/article/4moving-biotech-completes-enrollment-in-phase-2a-inflam-motion-study-evaluating-4bd7377c4dab05f8Pharma Surgeen2026-08-04T05:01:08.000Z4Moving Biotech Completes Enrollment in Phase 2a INFLAM MOTION Study Evaluating First-in-class Intra-articular GLP-1 Therapy Targeting Synovitis as a Driver of Pain and Disease Progression in Knee Osteoarthritishttps://www.pharmaradar360.com/article/4moving-biotech-dced3c53d13d0edfPharma Surgeen2026-08-04T05:01:08.000Z4MOVING-BIOTECHhttps://www.pharmaradar360.com/article/regarding-a-report-concerning-sumitomo-pharma-55498f8790dbeb7cPharma Surgeen2026-08-04T05:00:00.000ZRegarding a Report Concerning Sumitomo Pharmahttps://www.pharmaradar360.com/article/4moving-biotech-completes-enrollment-in-phase-2a-inflam-motion-study-evaluating-0f28b788959b60a5Pharma Surgeen2026-08-04T05:00:00.000Z4Moving Biotech Completes Enrollment in Phase 2a INFLAM MOTION Study Evaluating First-in-class Intra-articular GLP-1 Therapy Targeting Synovitis as a Driver of Pain and Disease Progression in Knee Osteoarthritishttps://www.pharmaradar360.com/article/have-you-heard-of-biotech-beauty-we-took-a-closer-look-273b6fccdba886b5Pharma Surgeen2026-08-04T04:39:43.000ZHave you heard of biotech beauty? We took a closer lookhttps://www.pharmaradar360.com/article/does-tukaram-mundhe-receive-threats-after-action-against-restaurants-maharashtra-91715512912c9eacPharma Surgeen2026-08-04T04:38:02.000ZDoes Tukaram Mundhe Receive Threats After Action Against Restaurants? Maharashtra FDA Chief Respondshttps://www.pharmaradar360.com/article/peptides-find-their-way-to-the-public-a38a5de7d0976a3dPharma Surgeen2026-08-04T04:05:00.000ZPeptides Find Their Way to the Publichttps://www.pharmaradar360.com/article/krystal-biotech-inc-unsponsored-bdr-revenue-breakdown-bmfbovespa-k1ys34-a75951c9b1bbc213Pharma Surgeen2026-08-04T03:39:04.000ZKrystal Biotech Inc Unsponsored BDR Revenue Breakdown – BMFBOVESPA:K1YS34https://www.pharmaradar360.com/article/ever-supreme-bio-s-july-revenue-hits-nt-99-25-million-a-2025-high-cell-therapy-d-ea583d4cedad45f5Pharma Surgeen2026-08-04T03:16:00.000ZEver Supreme Bio's July Revenue Hits NT$99.25 Million, a 2025 High; Cell Therapy Drug Advances to Phase 2a Clinical Trialhttps://www.pharmaradar360.com/article/amplia-therapeutics-partners-with-lilly-on-lung-cancer-combination-trial-859357a78be1196bPharma Surgeen2026-08-04T03:12:34.000ZAmplia Therapeutics partners with Lilly on lung cancer combination trialhttps://www.pharmaradar360.com/article/neurizon-advances-als-trial-in-q4-fy26-179787d24b64ff0cPharma Surgeen2026-08-04T03:12:00.000ZNeurizon advances ALS trial in Q4 FY26https://www.pharmaradar360.com/article/cytiva-partners-with-mycenax-biotech-to-build-ai-driven-and-future-ready-downstr-1e570b454b1e83efPharma Surgeen2026-08-04T03:01:33.000ZCytiva Partners with Mycenax Biotech to Build AI-Driven and Future-Ready Downstream Bioprocessinghttps://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-avarept-67d65f5d4ba4aa36Pharma Surgeen2026-08-04T03:00:00.000Z[SHINSA]English Translation of Review Report: Avarepthttps://www.pharmaradar360.com/article/krystal-biotech-inc-krys-q2-2026-earnings-call-highlights-v-1edf1c4533ca7860Pharma Surgeen2026-08-04T03:00:00.000ZKrystal Biotech Inc (KRYS) (Q2 2026) Earnings Call Highlights: Vhttps://www.pharmaradar360.com/article/sumitomo-pharma-s-enzomenib-gets-orphan-drug-designation-by-us-fda-c915c5e89ad58581Pharma Surgeen2026-08-04T02:46:21.000ZSumitomo Pharma's Enzomenib gets Orphan Drug Designation by US FDAhttps://www.pharmaradar360.com/article/stoke-therapeutics-announces-second-quarter-2026-financial-results-and-provides-548819893736a12dPharma Surgeen2026-08-04T02:30:55.000ZStoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updateshttps://www.pharmaradar360.com/article/amplia-teams-up-with-big-pharma-for-lung-cancer-trial-22c49f021e63d5baPharma Surgeen2026-08-04T02:23:45.000ZAmplia teams up with big pharma for lung cancer trialhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-zhejiang-tianyu-pharmaceutical-co-ltd-class-69fe1c13ba03471fPharma Surgeen2026-08-04T02:20:05.000ZEnterprise value to EBIT forward of Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A – SZSE:300702https://www.pharmaradar360.com/article/otsuka-unveils-unprecedented-phase-3-visionary-two-year-egfr-results-demonstrati-34692e78f06f183bPharma Surgeen2026-08-04T02:04:45.000ZOtsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathyhttps://www.pharmaradar360.com/article/maharashtra-fda-has-no-list-of-fssai-compliant-restaurants-despite-crackdown-6c6e5261fabe6a93Pharma Surgeen2026-08-04T02:01:00.000ZMaharashtra FDA has no list of FSSAI-compliant restaurants despite crackdownhttps://www.pharmaradar360.com/article/otsuka-sponsors-the-20th-asian-games-aichi-nagoya-2026-supporting-conditioning-a-ec4f1cfe8b4b60dePharma Surgeen2026-08-04T02:00:00.000ZOtsuka Sponsors the 20th Asian Games Aichi-Nagoya 2026 Supporting Conditioning and Performance with the Global Brand POCARI SWEAThttps://www.pharmaradar360.com/article/krystal-biotech-krys-stock-price-drops-as-premium-expectations-reset-a509dbcb81fac63aPharma Surgeen2026-08-04T01:01:51.000ZKrystal Biotech (KRYS) Stock Price Drops As Premium Expectations Resethttps://www.pharmaradar360.com/article/amplia-therapeutics-partners-with-eli-lilly-in-fak-kras-combination-lung-cancer-e200f7f2de36753aPharma Surgeen2026-08-04T00:44:05.000ZAmplia Therapeutics Partners with Eli Lilly in FAK-KRAS Combination Lung Cancer Trialhttps://www.pharmaradar360.com/article/chop-linked-drug-candidate-acquired-by-iceland-biotech-53bbd1d1ea1c0753Pharma Surgeen2026-08-04T00:27:00.000ZCHOP-linked drug candidate acquired by Iceland biotechhttps://www.pharmaradar360.com/article/fargo-sets-october-special-election-on-ward-system-approves-15m-biotech-tax-ince-d6d8d9175e8ad9daPharma Surgeen2026-08-04T00:13:44.000ZFargo sets October special election on ward system, approves $15M biotech tax incentivehttps://www.pharmaradar360.com/article/otsuka-unveils-unprecedented-phase-3-visionary-two-year-egfr-results-demonstrati-a2e5a108bb07ba54Pharma Surgeen2026-08-04T00:00:00.000ZOtsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathyhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-dcc1639380a83d51Pharma Surgeen2026-08-04T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-57197b1cdd67fc74Pharma Surgeen2026-08-04T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-b81846d6abaf0f3fPharma Surgeen2026-08-04T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-5639069ac7e9bc6aPharma Surgeen2026-08-04T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-066381ac7161a7a0Pharma Surgeen2026-08-04T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-3fb0638a56ceb4d9Pharma Surgeen2026-08-04T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-4243733f02228f9ePharma Surgeen2026-08-04T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-f93675dc33d79be9Pharma Surgeen2026-08-04T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-c417e420cf855c6bPharma Surgeen2026-08-04T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-95654be52e1b7086Pharma Surgeen2026-08-04T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-08a4cdab3be0ecd3Pharma Surgeen2026-08-04T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-19a7b6e3a400f9fdPharma Surgeen2026-08-04T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-2d193e276801d42fPharma Surgeen2026-08-04T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-e0f355ba0886fd05Pharma Surgeen2026-08-04T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/cleveland-clinic-one-of-the-nation-s-best-hospitals-9a3467ebc58b15bePharma Surgeen2026-08-04T00:00:00.000ZCleveland Clinic One of the Nation’s Best Hospitalshttps://www.pharmaradar360.com/article/is-krystal-biotech-krys-overvalued-after-q2-earnings-beat-eps-of-1-85-revenue-of-9ac9597e4f904258Pharma Surgeen2026-08-04T00:00:00.000ZIs Krystal Biotech (KRYS) Overvalued After Q2 Earnings Beat? EPS of $1.85 & Revenue of $119.2M; GF Score: 54/100https://www.pharmaradar360.com/article/a-comprehensive-study-on-the-development-of-stimuli-responsive-smart-polymer-sys-7a42d8b2eb1a422cPharma Surgeen2026-08-04T00:00:00.000ZA Comprehensive Study on the Development of Stimuli-Responsive Smart Polymer Systems for Controlled Drug Deliveryhttps://www.pharmaradar360.com/article/metal-complexes-of-coumarin-derivatives-an-extensive-review-4357c5a6fbdebf1fPharma Surgeen2026-08-04T00:00:00.000ZMetal Complexes of Coumarin derivatives-An Extensive Reviewhttps://www.pharmaradar360.com/article/peer-review-report-for-evaluation-and-clinical-relevance-of-plan-quality-indices-b17f2a26a7073755Pharma Surgeen2026-08-04T00:00:00.000ZPeer Review Report For: Evaluation and clinical relevance of plan quality indices in intracavitary brachytherapy for cervical cancer [version 1; peer review: 2 approved]https://www.pharmaradar360.com/article/beyond-diagnosis-why-clinical-curiosity-still-matters-in-psychiatry-4aa0fd8928983525Pharma Surgeen2026-08-04T00:00:00.000ZBeyond Diagnosis: Why Clinical Curiosity Still Matters in Psychiatryhttps://www.pharmaradar360.com/article/the-mediating-role-of-hope-in-the-association-between-resilience-and-psychologic-341eae7e8f9aa774Pharma Surgeen2026-08-04T00:00:00.000ZTHE MEDIATING ROLE OF HOPE IN THE ASSOCIATION BETWEEN RESILIENCE AND PSYCHOLOGICAL DISTRESS AMONG CLINICAL CLERKSHIP STUDENTShttps://www.pharmaradar360.com/article/the-evolution-of-proximal-femur-hemiepiphysiodesis-in-children-with-cerebral-pal-34a8cb830224725cPharma Surgeen2026-08-04T00:00:00.000ZThe Evolution of Proximal Femur Hemiepiphysiodesis in Children with Cerebral Palsyhttps://www.pharmaradar360.com/article/metabolic-indices-of-atherogenicity-insulin-resistance-and-inflammation-aip-tyg-d0c2b0908354c215Pharma Surgeen2026-08-04T00:00:00.000ZMetabolic Indices of Atherogenicity, Insulin Resistance, and Inflammation (AIP, TyG, and CTI) and the Risk of Renal Function Decline in Early-Stage CKM Syndrome: A Nationwide Prospective Cohort Studyhttps://www.pharmaradar360.com/article/the-stiim-up-protocol-exploratory-evaluation-of-the-potential-of-combined-calciu-8c4ca6df13d6be31Pharma Surgeen2026-08-04T00:00:00.000ZThe STIIM UP Protocol: Exploratory Evaluation of the Potential of Combined Calcium Hydroxyapatite, Hyaluronic Acid, and Botulinum Toxin A in Neck Rejuvenationhttps://www.pharmaradar360.com/article/eeg-connectivity-signatures-in-migraine-and-tension-type-headache-a-multimethod-7772e9e6f44a5f16Pharma Surgeen2026-08-04T00:00:00.000ZEEG Connectivity Signatures in Migraine and Tension-Type Headache: A Multimethod ROI-Based Functional Connectivity and Machine-Learning Analysishttps://www.pharmaradar360.com/article/clinical-and-lat1-biomarker-correlates-of-clinical-benefit-from-nanvuranlat-jph2-ba849d7fe34af933Pharma Surgeen2026-08-04T00:00:00.000ZClinical and LAT1 Biomarker Correlates of Clinical Benefit from Nanvuranlat (JPH203) in Advanced Biliary Tract Cancer: A Post Hoc Analysishttps://www.pharmaradar360.com/article/immersive-virtual-reality-as-an-auxiliary-intervention-for-college-students-with-511c46aed282a65aPharma Surgeen2026-08-04T00:00:00.000ZImmersive virtual reality as an auxiliary intervention for college students with mild-to-moderate depressive symptoms: a pilot randomized controlled trialhttps://www.pharmaradar360.com/article/spinal-intradural-hematoma-after-intrathecal-drug-delivery-system-implantation-i-c5d99583bd20c3c2Pharma Surgeen2026-08-04T00:00:00.000ZSpinal intradural hematoma after intrathecal drug delivery system implantation in a patient with possible heparin-induced thrombocytopenia: a case reporthttps://www.pharmaradar360.com/article/case-report-pembrolizumab-associated-seronegative-sicca-syndrome-during-continue-2136515cc1f6556dPharma Surgeen2026-08-04T00:00:00.000ZCase Report: Pembrolizumab-associated seronegative sicca syndrome during continued immunotherapy and after drug withdrawal in metastatic urothelial carcinomahttps://www.pharmaradar360.com/article/efficacy-and-safety-of-pain-management-in-perioperative-period-of-tace-in-patien-5e5458938fa13600Pharma Surgeen2026-08-04T00:00:00.000ZEfficacy and safety of pain management in perioperative period of TACE in patients with HCC: a single-center, parallel-group, randomized trialhttps://www.pharmaradar360.com/article/fabry-nephropathy-as-the-clinical-anchor-for-kidney-centered-metabolic-surveilla-1ba2ad08f33433dfPharma Surgeen2026-08-04T00:00:00.000ZFabry nephropathy as the clinical anchor for kidney-centered metabolic surveillance: linking genetic heterogeneity to early risk identificationhttps://www.pharmaradar360.com/article/autoimmune-hypothyroidism-and-endometriosis-evidence-from-bidirectional-mendelia-aec4bc2c7394cc7aPharma Surgeen2026-08-04T00:00:00.000ZAutoimmune hypothyroidism and endometriosis: evidence from bidirectional Mendelian randomization and an independent clinical cohort analysishttps://www.pharmaradar360.com/article/association-between-a-clinical-pharmacist-led-multimodal-remote-medication-inter-24f025931802ad4bPharma Surgeen2026-08-04T00:00:00.000ZAssociation between a clinical pharmacist–led multimodal remote medication intervention and individualized treatment outcomes in patients with type 2 diabetes mellitushttps://www.pharmaradar360.com/article/is-age-still-a-barrier-in-ventricular-tachycardia-ablation-a-study-of-safety-eff-72dd5fb9d14d8c10Pharma Surgeen2026-08-04T00:00:00.000ZIs age still a barrier in ventricular tachycardia ablation? A study of safety, efficacy and clinical outcomes in the elderlyhttps://www.pharmaradar360.com/article/protocol-for-a-small-scale-mixed-methods-efficacy-trial-of-a-novel-co-designed-d-b0b246f836281506Pharma Surgeen2026-08-04T00:00:00.000ZProtocol for a small-scale mixed methods efficacy trial of a novel co-designed digital health intervention targeting emotion dysregulation in adolescents with ADHD symptomshttps://www.pharmaradar360.com/article/design-synthesis-amp-biological-evaluation-of-oxazole-derivatives-for-antimicrob-325df14dd821d80cPharma Surgeen2026-08-04T00:00:00.000ZDESIGN, SYNTHESIS &amp; BIOLOGICAL EVALUATION OF OXAZOLE DERIVATIVES FOR ANTIMICROBIAL ACTIVITYhttps://www.pharmaradar360.com/article/hptlc-fingerprint-profiling-and-phytochemical-characterization-of-haridradi-chur-ca11724b4011778dPharma Surgeen2026-08-04T00:00:00.000ZHPTLC Fingerprint Profiling and Phytochemical Characterization of Haridradi Churnahttps://www.pharmaradar360.com/article/a-correlation-study-parental-bonding-self-esteem-and-academic-motivation-among-a-5ce53713862cb80aPharma Surgeen2026-08-04T00:00:00.000ZA correlation study: Parental Bonding, Self-Esteem and Academic Motivation among adolescentshttps://www.pharmaradar360.com/article/thanatophoric-dysplasia-prevalence-clinical-characteristics-and-molecular-findin-74f0f42c9082561bPharma Surgeen2026-08-04T00:00:00.000ZThanatophoric dysplasia: prevalence, clinical characteristics, and molecular findings in a public hospital from Western Mexicohttps://www.pharmaradar360.com/article/clinical-and-molecular-characterization-of-six-mexican-patients-with-fgfr2-relat-8fa0c2156b950935Pharma Surgeen2026-08-04T00:00:00.000ZClinical and molecular characterization of six Mexican patients with FGFR2-related syndromic craniosynostosishttps://www.pharmaradar360.com/article/desafios-asistenciales-en-el-manejo-del-adenocarcinoma-de-pulmon-en-estadio-iii-02a3d42b53d184a7Pharma Surgeen2026-08-04T00:00:00.000ZDesafíos asistenciales en el manejo del adenocarcinoma de pulmón en estadio III con mutación de EGFR: integración de la cirugía y la terapia adyuvante en la era post-ADAURAhttps://www.pharmaradar360.com/article/mas-alla-del-0-respuesta-mantenida-a-quimioinmunoterapia-en-pd-l1-negativo-e3750f0f79fafb42Pharma Surgeen2026-08-04T00:00:00.000ZMás allá del 0%: respuesta mantenida a quimioinmunoterapia en PD-L1 negativohttps://www.pharmaradar360.com/article/largo-superviviente-en-carcinoma-microcitico-de-pulmon-avanzado-papel-de-la-inmu-3c8a236edbd4800bPharma Surgeen2026-08-04T00:00:00.000ZLargo superviviente en carcinoma microcítico de pulmón avanzado: papel de la inmunoterapia de mantenimiento y tratamiento local de la oligoprogresiónhttps://www.pharmaradar360.com/article/prognostic-stratification-in-a-diabetic-kidney-disease-trial-using-plasma-concen-5e3a15921fe545f0Pharma Surgeen2026-08-04T00:00:00.000ZPrognostic stratification in a diabetic kidney disease trial using plasma concentrations of soluble tumor necrosis factor receptor 1https://www.pharmaradar360.com/article/a-cross-sectional-pharmacovigilance-study-of-adverse-drug-reactions-in-patients-fc75327c120aa1d0Pharma Surgeen2026-08-04T00:00:00.000ZA Cross-Sectional Pharmacovigilance Study of Adverse Drug Reactions in Patients with Mental Health Disorders at the Social Rehabilitation Yogyakartahttps://www.pharmaradar360.com/article/religion-spirituality-addiction-guilt-and-shame-a-systematic-review-of-mechanism-44ca3ef6a51ac5cePharma Surgeen2026-08-04T00:00:00.000ZReligion, Spirituality, Addiction, Guilt, and Shame: A Systematic Review of Mechanisms, Outcomes, and Clinical Implicationshttps://www.pharmaradar360.com/article/new-drug-elafibranor-for-primary-biliary-cholangitis-9463213deca3dd49Pharma Surgeen2026-08-04T00:00:00.000ZNew Drug: Elafibranor for primary biliary cholangitishttps://www.pharmaradar360.com/article/structural-characterization-of-new-8-17-epoxybriarane-diterpenoids-from-the-octo-0f071b6b35aa03bdPharma Surgeen2026-08-04T00:00:00.000ZStructural Characterization of New 8,17-Epoxybriarane Diterpenoids from the Octocoral &lt;i&gt;Briareum stechei&lt;/i&gt;https://www.pharmaradar360.com/article/the-effect-of-fenugreek-oral-capsule-on-the-sleep-quality-of-primiparous-women-i-8dcc3545e5b761bePharma Surgeen2026-08-04T00:00:00.000ZThe effect of fenugreek oral capsule on the sleep quality of primiparous women in the postpartum period: a triple‑blind randomized controlled trialhttps://www.pharmaradar360.com/article/correlation-between-high-risk-human-papillomavirus-hpv-viral-load-and-cervical-l-f119909e1bcfc2a8Pharma Surgeen2026-08-04T00:00:00.000ZCorrelation between high-risk Human Papillomavirus (HPV) viral load and cervical lesions across different subtypes, along with the development of a clinical prediction modelhttps://www.pharmaradar360.com/article/effect-of-a-free-sugar-restricted-diet-on-anthropometric-parameters-lipid-profil-511f93d69dc5ae05Pharma Surgeen2026-08-04T00:00:00.000ZEffect of a free sugar-restricted diet on anthropometric parameters, lipid profile, and glycemic control in women with polycystic ovary syndrome: a randomized controlled trialhttps://www.pharmaradar360.com/article/effect-of-postpartum-probiotic-supplementation-on-breastmilk-composition-and-inf-c2dc26c7b92eebe2Pharma Surgeen2026-08-04T00:00:00.000ZEffect of postpartum probiotic supplementation on breastmilk composition and infant health: a pilot randomized controlled trialhttps://www.pharmaradar360.com/article/effects-of-dairy-product-intake-and-home-based-resistance-exercise-on-the-physic-6ddcb68916d98512Pharma Surgeen2026-08-04T00:00:00.000ZEffects of dairy product intake and home-based resistance exercise on the physical function in Japanese community-dwelling older adults: results of a real-world randomized controlled trialhttps://www.pharmaradar360.com/article/selected-clinical-parameters-of-cardiology-patients-their-health-promoting-behav-b9a22c0a1d1adebbPharma Surgeen2026-08-04T00:00:00.000ZSelected clinical parameters of cardiology patients, their health-promoting behaviors and quality of life in relation to body mass indexhttps://www.pharmaradar360.com/article/the-effect-of-orthodontic-tooth-movement-on-intrabony-periodontal-defects-after-3a7653689fcd08f8Pharma Surgeen2026-08-04T00:00:00.000ZThe Effect of Orthodontic Tooth Movement on Intrabony Periodontal Defects After Guided Tissue Regeneration. Part <scp>II</scp> : The Evaluation of Clinical and Radiological Parameters in a Randomised Controlled Clinical Trialhttps://www.pharmaradar360.com/article/clinical-decision-support-to-reduce-opioid-prescribing-at-discharge-for-inpatien-7b644f2593912463Pharma Surgeen2026-08-04T00:00:00.000ZClinical Decision Support to Reduce Opioid Prescribing at Discharge for Inpatients Undergoing Surgery (LESS Study): An Interrupted Time Series Analysishttps://www.pharmaradar360.com/article/cerebral-aspergillosis-under-ibrutinib-therapy-clinical-features-and-management-cef0c4618822546bPharma Surgeen2026-08-04T00:00:00.000ZCerebral aspergillosis under ibrutinib therapy: clinical features and management challengeshttps://www.pharmaradar360.com/article/latent-profiles-of-social-isolation-and-loneliness-and-their-associations-with-i-3c8fe81adc4acb57Pharma Surgeen2026-08-04T00:00:00.000ZLatent profiles of social isolation and loneliness and their associations with inflammation and clinical outcomes in older patients with heart failure: A prospective longitudinal studyhttps://www.pharmaradar360.com/article/fear-of-clofazimine-induced-skin-discoloration-as-a-barrier-to-leprosy-treatment-59a09b4ac70cc863Pharma Surgeen2026-08-04T00:00:00.000ZFear of clofazimine-induced skin discoloration as a barrier to leprosy treatment: urgent need for alternative therapeutic optionshttps://www.pharmaradar360.com/article/the-social-insensitivity-of-clinical-delusions-c668a23c154aad34Pharma Surgeen2026-08-04T00:00:00.000ZThe Social Insensitivity of Clinical Delusionshttps://www.pharmaradar360.com/article/the-social-determinants-and-focus-of-clinical-delusions-872c20d60a1b5eb3Pharma Surgeen2026-08-04T00:00:00.000ZThe Social Determinants and Focus of Clinical Delusionshttps://www.pharmaradar360.com/article/individualistic-accounts-of-clinical-delusions-417b1b5d3ec7d104Pharma Surgeen2026-08-04T00:00:00.000ZIndividualistic Accounts of Clinical Delusionshttps://www.pharmaradar360.com/article/ubiquitin-family-as-novel-protein-partners-for-molecular-glues-fa5d203a1dc0501aPharma Surgeen2026-08-04T00:00:00.000ZUbiquitin family as novel protein partners for molecular glueshttps://www.pharmaradar360.com/article/the-microbiological-spectrum-and-clinical-course-of-adolescents-and-adults-with-be1aa96ebd7f1f1fPharma Surgeen2026-08-04T00:00:00.000ZThe microbiological spectrum and clinical course of adolescents and adults with peritonsillar abscesseshttps://www.pharmaradar360.com/article/the-landscape-and-plasticity-of-transposable-element-expression-in-an-adult-stem-5045c61839f4f103Pharma Surgeen2026-08-04T00:00:00.000ZThe landscape and plasticity of transposable element expression in an adult stem cell of high physiological and clinical significancehttps://www.pharmaradar360.com/article/global-trends-in-artificial-intelligence-applications-in-medical-imaging-and-imp-dcbd060082882ab4Pharma Surgeen2026-08-04T00:00:00.000ZGlobal trends in artificial intelligence applications in medical imaging and implications for clinical practicehttps://www.pharmaradar360.com/article/identification-of-novel-diagnostic-markers-in-progressive-bone-mineral-density-l-cbe1a5b4eae73aafPharma Surgeen2026-08-04T00:00:00.000ZIdentification of novel diagnostic markers in progressive bone mineral density loss via serum proteomics analysis using orbitrap mass spectrometryhttps://www.pharmaradar360.com/article/oxidative-stress-and-il-36-mediated-inflammation-in-osteoarthritis-association-w-d8a16150a407c636Pharma Surgeen2026-08-04T00:00:00.000ZOxidative Stress and IL-36α–Mediated Inflammation in Osteoarthritis: Association with Tryptophan–Kynurenine Metabolismhttps://www.pharmaradar360.com/article/rapid-antimicrobial-susceptibility-testing-bridging-commercial-platforms-and-eme-bc1fce77b56de9c1Pharma Surgeen2026-08-04T00:00:00.000ZRapid antimicrobial susceptibility testing: bridging commercial platforms and emerging technologies toward clinical implementationhttps://www.pharmaradar360.com/article/comparative-analysis-of-supervised-machine-learning-algorithms-for-transdermal-d-524da7d5b3afbe27Pharma Surgeen2026-08-04T00:00:00.000ZComparative analysis of supervised machine learning algorithms for transdermal drug delivery in brain disordershttps://www.pharmaradar360.com/article/association-of-urinary-albumin-to-creatinine-ratio-with-all-cause-and-cardiovasc-c9d04bba7551b0a3Pharma Surgeen2026-08-04T00:00:00.000ZAssociation of urinary albumin-to-creatinine ratio with all-cause and cardiovascular disease mortality risk in patients with osteoarthritis: a prospective cohort studyhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-add-on-topiramate-vs-metformin-on-cardiometabolic-profile-6af83a815dee7ac4Pharma Surgeen2026-08-04T00:00:00.000ZEfficacy and safety of add-on topiramate vs. metformin on cardiometabolic profile in patients of schizophrenia on atypical antipsychotics with metabolic syndrome: an active-controlled, rater-blinded, parallel-design randomized controlled trialhttps://www.pharmaradar360.com/article/investigating-changes-in-the-blood-brain-barrier-in-schizophrenia-spectrum-disor-95bde52333918142Pharma Surgeen2026-08-04T00:00:00.000ZInvestigating changes in the blood-brain barrier in schizophrenia spectrum disorders: design and methodology of a longitudinal dynamic contrast-enhanced MRI studyhttps://www.pharmaradar360.com/article/a-mortality-model-for-relapsed-or-refractory-multiple-myeloma-emulation-of-subje-d90612a075563aa2Pharma Surgeen2026-08-04T00:00:00.000ZA mortality model for relapsed or refractory multiple myeloma: emulation of subjective life expectancy criteria from a clinical trial in real-world datahttps://www.pharmaradar360.com/article/subtractive-proteomics-assisted-putative-drug-target-and-inhibitor-identificatio-21638f0b2cdff550Pharma Surgeen2026-08-04T00:00:00.000ZSubtractive proteomics-assisted putative drug target and inhibitor identification: a study based on six Candida specieshttps://www.pharmaradar360.com/article/tongue-grooving-during-drug-induced-sleep-endoscopy-a-novel-tool-to-evaluate-the-34c6260008caa17aPharma Surgeen2026-08-04T00:00:00.000ZTongue Grooving During Drug‐Induced Sleep Endoscopy: A Novel Tool to Evaluate the Airwayhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-cisen-pharmaceutical-ltd-class-a-sse-603367-b1f0390851563376Pharma Surgeen2026-08-03T23:47:37.000ZPrice to earnings forward of Cisen Pharmaceutical Ltd. Class A – SSE:603367https://www.pharmaradar360.com/article/what-are-the-biggest-challenges-pharmaceutical-manufacturers-are-facing-today-f2bd80a3f7feb99fPharma Surgeen2026-08-03T23:39:14.000ZWhat Are the Biggest Challenges Pharmaceutical Manufacturers Are Facing Today?https://www.pharmaradar360.com/article/fda-approves-pluvicto-for-early-stage-metastatic-prostate-cancer-7f2e73f98ff22d12Pharma Surgeen2026-08-03T23:11:02.000ZFDA Approves Pluvicto for Early-Stage Metastatic Prostate Cancerhttps://www.pharmaradar360.com/article/amplia-announces-agreement-with-lilly-to-test-narmafotinib-combination-in-lung-c-e500ed252a76cfefPharma Surgeen2026-08-03T22:59:39.000ZAmplia announces agreement with Lilly to test narmafotinib combination in lung cancerhttps://www.pharmaradar360.com/article/oric-pharmaceuticals-oric-launches-pivotal-phase-3-trial-amid-mixed-market-signa-5bc75cb77e92676ePharma Surgeen2026-08-03T22:51:48.000ZORIC Pharmaceuticals (ORIC) Launches Pivotal Phase 3 Trial Amid Mixed Market Signalshttps://www.pharmaradar360.com/article/supreme-court-preserves-broad-access-to-abortion-drug-mifepristone-7f64cc35a1f5e3e3Pharma Surgeen2026-08-03T22:06:29.000ZSupreme Court preserves broad access to abortion drug mifepristonehttps://www.pharmaradar360.com/article/salicylic-acid-pharmaceutical-market-to-double-by-2035-on-dermatology-api-demand-657bd2fc4fa4a071Pharma Surgeen2026-08-03T22:01:15.000ZSalicylic Acid Pharmaceutical Market to Double by 2035 on Dermatology API Demandhttps://www.pharmaradar360.com/article/mail-order-pharmacy-influencing-fda-policy-sells-thousands-of-abortion-pills-mon-961523f8add0047aPharma Surgeen2026-08-03T21:50:01.000ZMail-order pharmacy influencing FDA policy sells 'thousands of abortion pills monthlyhttps://www.pharmaradar360.com/article/moleculin-biotech-raises-9-3-million-equity-signs-placement-purchase-and-lock-up-f1762b0f1bfd853bPharma Surgeen2026-08-03T21:13:01.000ZMoleculin Biotech Raises $9.3 Million Equity; Signs Placement, Purchase and Lock-Up Agreementshttps://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-stock-outperforms-competitors-on-strong-trading-e486c1cf6569699cPharma Surgeen2026-08-03T21:04:00.000ZWest Pharmaceutical Services Inc. stock outperforms competitors on strong trading dayhttps://www.pharmaradar360.com/article/korea-biotech-chiefs-buy-shares-as-fda-setbacks-sink-stocks-chosunbiz-87f70062444752d0Pharma Surgeen2026-08-03T21:03:00.000ZKorea biotech chiefs buy shares as FDA setbacks sink stocks - CHOSUNBIZhttps://www.pharmaradar360.com/article/why-is-krystal-biotech-stock-sliding-today-c7baa2fb70a2bff6Pharma Surgeen2026-08-03T20:59:31.000ZWhy is Krystal Biotech stock sliding today?https://www.pharmaradar360.com/article/san-diego-cancer-biotech-blossomhill-seeks-public-listing-to-support-clinical-wo-6c655c57f793f6a6Pharma Surgeen2026-08-03T20:48:59.000ZSan Diego Cancer Biotech BlossomHill Seeks Public Listing to Support Clinical Workhttps://www.pharmaradar360.com/article/non-opioid-developer-latigo-biotherapeutics-files-for-up-to-288m-float-as-lead-d-b9a16a7edc614c96Pharma Surgeen2026-08-03T20:48:21.000ZNon-Opioid Developer Latigo Biotherapeutics Files for Up to $288M Float as Lead Drug Nears Phase 3https://www.pharmaradar360.com/article/fujifilm-and-taiho-pharmaceutical-enter-into-strategic-partnership-for-developme-af56c030c9a21382Pharma Surgeen2026-08-03T20:38:41.000ZFujifilm and Taiho Pharmaceutical Enter into Strategic Partnership for Development of Next-Generation Antibody-Drug Conjugate (ADC) Manufacturing Technologieshttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32Pharma Surgeen2026-08-03T20:28:59.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/three-noteworthy-biotechs-just-reported-earnings-and-only-one-recovered-954524825f29c6c3Pharma Surgeen2026-08-03T20:23:00.000ZThree Noteworthy Biotechs Just Reported Earnings — And Only One Recoveredhttps://www.pharmaradar360.com/article/astrazeneca-and-bristol-myers-squibb-held-merger-talks-pharmexec-a6eeae218ea05567Pharma Surgeen2026-08-03T20:07:22.000ZAstraZeneca and Bristol Myers Squibb Held Merger Talks | PharmExechttps://www.pharmaradar360.com/article/jazz-pharmaceuticals-announces-second-quarter-2026-financial-results-3c2bc3c2ef0bf057Pharma Surgeen2026-08-03T20:05:00.000ZJazz Pharmaceuticals Announces Second Quarter 2026 Financial Resultshttps://www.pharmaradar360.com/article/oric-starts-global-prostate-cancer-trial-expected-to-enroll-about-600-c189a9bc20800c9aPharma Surgeen2026-08-03T20:05:00.000ZORIC Starts Global Prostate Cancer Trial Expected to Enroll About 600https://www.pharmaradar360.com/article/oric-pharmaceuticals-reports-second-quarter-2026-financial-results-and-operation-fad99a5991c04c94Pharma Surgeen2026-08-03T20:05:00.000ZORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updateshttps://www.pharmaradar360.com/article/drug-spending-increasingly-rewards-pharmaceutical-innovation-over-me-too-medicin-91fb11175cba696cPharma Surgeen2026-08-03T20:00:01.000ZDrug spending increasingly rewards pharmaceutical innovation over 'me-too' medicineshttps://www.pharmaradar360.com/article/14-new-weight-loss-drugs-8f97f67645d6c678Pharma Surgeen2026-08-03T19:36:10.000Z14 New Weight Loss Drugshttps://www.pharmaradar360.com/article/claris-bio-raises-118m-to-advance-first-ever-lscd-therapy-bfcca7b3be802b43Pharma Surgeen2026-08-03T19:26:06.000ZClaris Bio raises $118M to advance first-ever LSCD therapyhttps://www.pharmaradar360.com/article/retatrutide-for-weight-loss-availability-dosage-and-more-9de68bf24030fa2bPharma Surgeen2026-08-03T19:16:20.000ZRetatrutide for Weight Loss: Availability, Dosage, and Morehttps://www.pharmaradar360.com/article/fda-green-lights-1st-new-sunscreen-ingredient-in-years-4d1f139bc83cf3e9Pharma Surgeen2026-08-03T18:44:09.000ZFDA green-lights 1st new sunscreen ingredient in yearshttps://www.pharmaradar360.com/article/cordis-project-cardio-oncology-multidisciplinary-patient-assistance-solution-0fae8f4b4eab75caPharma Surgeen2026-08-03T18:28:05.000ZCORDIS project: Cardio-Oncology Multidisciplinary Patient ASsistance Solutionhttps://www.pharmaradar360.com/article/altimmune-alt-begins-enrollment-in-phase-3-trial-amid-high-pri-c1ab1038e257c9a4Pharma Surgeen2026-08-03T18:26:15.000ZAltimmune (ALT) Begins Enrollment in Phase 3 Trial Amid High Prihttps://www.pharmaradar360.com/article/building-mutual-understanding-between-scientists-and-study-coordinators-to-addre-475649d1f7160429Pharma Surgeen2026-08-03T18:13:52.000ZBuilding Mutual Understanding Between Scientists and Study Coordinators to Address the CRC Workforce Crisishttps://www.pharmaradar360.com/article/fda-concerns-unapproved-glp-1-drugs-used-for-weight-loss-official-view-ojoqvbgob-03dfccbf8c9a36c2Pharma Surgeen2026-08-03T18:00:57.000ZFDA Concerns Unapproved GLP-1 Drugs Used for Weight Loss Official - View OJoqVBGObhttps://www.pharmaradar360.com/article/american-regent-inc-animal-health-issues-nationwide-recall-of-two-lots-of-adequa-139c93c06d327e6bPharma Surgeen2026-08-03T17:22:32.000ZAmerican Regent, Inc. Animal Health Issues Nationwide Recall of Two Lots of Adequan® Canine and Two Lots of Adequan® I.M. Due to Visible Glass Fiber Material in the Producthttps://www.pharmaradar360.com/article/fda-panel-backs-6-peptides-despite-its-own-scientists-objections-400f46662434c837Pharma Surgeen2026-08-03T16:52:00.000ZFDA panel backs 6 peptides despite its own scientists’ objectionshttps://www.pharmaradar360.com/article/an-astrazeneca-bristol-myers-megamerger-wall-street-isn-t-thrilled-cb3332232416332ePharma Surgeen2026-08-03T16:29:12.000ZAn AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.https://www.pharmaradar360.com/article/the-2026-forecast-revisited-dealmaking-direct-to-patient-and-patient-affordabili-c5a0f9ae0fca1bdaPharma Surgeen2026-08-03T16:06:45.000ZThe 2026 Forecast Revisited: Dealmaking, Direct-to-Patient and Patient Affordabilityhttps://www.pharmaradar360.com/article/fda-proposes-restrictions-on-compounding-popular-weight-loss-medications-xnbkpxp-7ab1ff1c7eba17a4Pharma Surgeen2026-08-03T15:40:33.000ZFDA Proposes Restrictions on Compounding Popular Weight Loss Medications *xNBkPxpOl*https://www.pharmaradar360.com/article/decision-human-medicines-register-of-electronic-export-certificates-59d0f7976611a0b7Pharma Surgeen2026-08-03T15:36:14.000ZDecision: Human medicines: register of electronic export certificateshttps://www.pharmaradar360.com/article/maritide-weight-loss-what-the-latest-phase-2-data-means-for-long-term-management-64a3efab5ea0f759Pharma Surgeen2026-08-03T15:31:59.000ZMaritide Weight Loss: What the Latest Phase 2 Data Means for Long-Term Management *K3K37KO9J*https://www.pharmaradar360.com/article/pfizer-weight-loss-drug-practical-insights-on-this-new-option-view-gojdj7h0v-585e0bf73dd5f2eaPharma Surgeen2026-08-03T15:30:03.000ZPfizer Weight Loss Drug: Practical Insights on This New Option - View GOJdJ7h0vhttps://www.pharmaradar360.com/article/depo-provera-lawsuit-settlement-august-2026-litigation-update-1f899de08f3ef039Pharma Surgeen2026-08-03T15:19:58.000ZDepo Provera Lawsuit Settlement | August 2026 Litigation Updatehttps://www.pharmaradar360.com/article/decision-marketing-authorisations-granted-in-2026-55acec19e967141aPharma Surgeen2026-08-03T15:18:28.000ZDecision: Marketing authorisations Granted in 2026https://www.pharmaradar360.com/article/two-biotech-names-on-josh-brown-s-best-stocks-list-are-making-meaningful-highs-t-2a3d7615a4a7aa78Pharma Surgeen2026-08-03T15:18:04.000ZTwo biotech names on Josh Brown's Best Stocks list are making meaningful highs this summerhttps://www.pharmaradar360.com/article/astrazeneca-plc-stock-azn-moved-down-by-8-54-on-aug-3-key-drivers-unveiled-a1315ea5840d6c71Pharma Surgeen2026-08-03T15:15:24.000ZAstraZeneca PLC Stock (AZN) Moved Down by 8.54% on Aug 3: Key Drivers Unveiledhttps://www.pharmaradar360.com/article/decision-parallel-import-licences-granted-in-2026-0fd86ddc9d9dd737Pharma Surgeen2026-08-03T15:13:01.000ZDecision: Parallel import licences granted in 2026https://www.pharmaradar360.com/article/nice-recommends-heart-drug-aficamten-with-simultaneous-mhra-approval-465095fb0031d17ePharma Surgeen2026-08-03T15:12:16.000ZNICE recommends heart drug aficamten with simultaneous MHRA approvalhttps://www.pharmaradar360.com/article/digital-systems-in-general-practice-could-reduce-medication-errors-36fc9c338507e06aPharma Surgeen2026-08-03T15:10:47.000ZDigital systems in general practice could reduce medication errorshttps://www.pharmaradar360.com/article/diamedica-therapeutics-dmac-biotech-with-breakthrough-potential-596e41c42c214b7ePharma Surgeen2026-08-03T15:09:16.000ZDiaMedica Therapeutics (DMAC): BioTech with Breakthrough Potentialhttps://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4Pharma Surgeen2026-08-03T14:50:08.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/fda-grants-breakthrough-status-to-lilly-pancreatic-cancer-drug-eb03620c9981f39cPharma Surgeen2026-08-03T14:48:09.000ZFDA Grants Breakthrough Status to Lilly Pancreatic Cancer Drughttps://www.pharmaradar360.com/article/ceruvia-raises-8-million-to-advance-phase-1-2-trial-of-cluster-headache-therapy-bd39e02ec519ab01Pharma Surgeen2026-08-03T14:35:45.000ZCeruvia Raises $8 Million to Advance Phase 1/2 Trial of Cluster Headache Therapyhttps://www.pharmaradar360.com/article/4-biotech-stocks-likely-to-outpace-q2-earnings-estimates-5f60b62ceec8860aPharma Surgeen2026-08-03T14:34:00.000Z4 Biotech Stocks Likely to Outpace Q2 Earnings Estimateshttps://www.pharmaradar360.com/article/weight-loss-drug-fda-approval-what-it-means-for-your-health-journey-in-2026-fpjj-4c74728fd8034764Pharma Surgeen2026-08-03T14:31:27.000ZWeight Loss Drug FDA Approval: What It Means for Your Health Journey in 2026 *fpjJUImpo*https://www.pharmaradar360.com/article/latigo-blossomhill-launch-us-ipos-as-biotech-listings-rebound-d99842670da15370Pharma Surgeen2026-08-03T14:25:37.000ZLatigo, BlossomHill launch US IPOs as biotech listings reboundhttps://www.pharmaradar360.com/article/form-424b5-moleculin-biotech-inc-for-3-august-by-investing-com-86c334fc957b9dc9Pharma Surgeen2026-08-03T14:21:53.000ZForm 424B5 Moleculin Biotech Inc For: 3 August By Investing.comhttps://www.pharmaradar360.com/article/faq-pharma-s-july-31-tariff-deadline-has-passed-now-what-f6da3b14d1c67b12Pharma Surgeen2026-08-03T14:21:45.000ZFAQ: Pharma's July 31 Tariff Deadline Has Passed. Now What?https://www.pharmaradar360.com/article/era-pooling-project-to-support-compliance-with-new-environmental-requirements-246eccca54ca1a31Pharma Surgeen2026-08-03T14:07:06.000ZERA Pooling Project to support compliance with new environmental requirementshttps://www.pharmaradar360.com/article/ceruvia-raises-8-million-to-complete-integrated-phase-1-2-trial-of-proprietary-n-e5dc5c9f88eb5a49Pharma Surgeen2026-08-03T14:01:36.000ZCeruvia Raises $8 Million to Complete Integrated Phase 1/2 Trial of Proprietary Non-Hallucinogenic LSD Analog for Cluster Headachehttps://www.pharmaradar360.com/article/spring-house-biotech-chromatan-chases-10m-round-after-15-years-08a1ab4f9bb5a950Pharma Surgeen2026-08-03T14:00:00.000ZSpring House Biotech ChromaTan Chases $10M Round After 15 Yearshttps://www.pharmaradar360.com/article/work-ethic-becomes-a-flashpoint-as-china-s-biotech-pace-quickens-327b4e72a5e30da2Pharma Surgeen2026-08-03T14:00:00.000ZWork ethic becomes a flashpoint as China’s biotech pace quickenshttps://www.pharmaradar360.com/article/altimmune-alt-begins-enrollment-in-phase-3-trial-amid-high-pri-88602a032bd6542fPharma Surgeen2026-08-03T13:50:44.000ZAltimmune (ALT) Begins Enrollment in Phase 3 Trial Amid High Prihttps://www.pharmaradar360.com/article/why-is-krystal-biotech-krys-dropping-7-0-983788c8610c0f04Pharma Surgeen2026-08-03T13:48:17.000ZWhy Is Krystal Biotech (KRYS) Dropping 7.0%?https://www.pharmaradar360.com/article/500-000-lost-a-day-the-economics-of-clinical-trial-execution-is-pharma-s-expensi-0aef23324ccef47ePharma Surgeen2026-08-03T13:46:12.000Z$500,000 Lost a Day: The Economics of Clinical Trial Execution Is Pharma's Expensive Secrethttps://www.pharmaradar360.com/article/4-biotech-stocks-likely-to-outpace-q2-earnings-estimates-fa1656b88958295cPharma Surgeen2026-08-03T13:42:40.000Z4 Biotech Stocks Likely to Outpace Q2 Earnings Estimateshttps://www.pharmaradar360.com/article/canada-authorizes-first-generic-weight-loss-drug-impacting-pharmaceutical-stocks-c937294bb1a1b7fePharma Surgeen2026-08-03T13:41:20.000ZCanada Authorizes First Generic Weight-Loss Drug Impacting Pharmaceutical Stocks *3yOXwZZFr*https://www.pharmaradar360.com/article/acurx-receives-fda-guidance-on-single-phase-3-trial-pathway-34c2c0468046459aPharma Surgeen2026-08-03T13:39:40.000ZAcurx receives FDA guidance on single Phase 3 trial pathwayhttps://www.pharmaradar360.com/article/graham-heap-joins-campfield-as-r-d-president-to-advance-prifemilast-phase-2-prog-7b47cbab7c259741Pharma Surgeen2026-08-03T13:35:52.000ZGraham Heap Joins cAMPfield as R&D President to Advance Prifemilast Phase 2 Programhttps://www.pharmaradar360.com/article/biotech-peach-yogurt-whey-and-dragon-fruit-lychee-creatine-b30dc000d655df8fPharma Surgeen2026-08-03T13:26:00.000ZBioTech Peach Yogurt Whey and Dragon Fruit Lychee Creatinehttps://www.pharmaradar360.com/article/is-there-a-pharma-mega-merger-in-the-making-e85ff7eab7dd650bPharma Surgeen2026-08-03T13:23:25.000ZIs there a pharma mega-merger in the making?https://www.pharmaradar360.com/article/is-organizational-readiness-pharma-s-real-ai-barrier-in-2026-003f3d408126b3a1Pharma Surgeen2026-08-03T13:18:53.000ZIs Organizational Readiness Pharma's Real AI Barrier in 2026?https://www.pharmaradar360.com/article/blossomhill-eyes-112m-ipo-harvest-to-fund-tagrisso-challenger-bd128eeea63c9ac6Pharma Surgeen2026-08-03T13:18:47.000ZBlossomHill eyes $112M IPO harvest to fund Tagrisso challengerhttps://www.pharmaradar360.com/article/biotech-giant-amgen-says-patient-data-stolen-from-third-party-cloud-systems-a56a54538055f5caPharma Surgeen2026-08-03T13:09:03.000ZBiotech giant Amgen says patient data stolen from third-party cloud systemshttps://www.pharmaradar360.com/article/sino-biological-launches-precisely-characterised-full-length-p-tau217-protein-f6b1fa32e972a688Pharma Surgeen2026-08-03T13:08:38.000ZSino Biological launches precisely characterised full-length p-Tau217 proteinhttps://www.pharmaradar360.com/article/two-biotech-ipos-test-the-market-s-reopening-3a3fb6dfb4c4bbccPharma Surgeen2026-08-03T13:00:44.000ZTwo Biotech IPOs Test The Market’s Reopeninghttps://www.pharmaradar360.com/article/fda-effort-to-recall-tavneos-challenged-by-drug-maker-10c9ff45ff5850d1Pharma Surgeen2026-08-03T13:00:00.000ZFDA Effort to Recall Tavneos Challenged by Drug Makerhttps://www.pharmaradar360.com/article/codexis-appoints-david-butler-phd-to-strategic-advisory-board-175ecfa61d0ff464Pharma Surgeen2026-08-03T13:00:00.000ZCodexis Appoints David Butler, PhD, to Strategic Advisory Boardhttps://www.pharmaradar360.com/article/biontech-picks-sobi-ceo-oelkers-to-lead-as-founders-plot-new-mrna-biotech-91fcdaa33164ad01Pharma Surgeen2026-08-03T12:57:06.000ZBioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotechhttps://www.pharmaradar360.com/article/moleculin-biotech-reports-positive-pivotal-phase-2-3-trial-results-for-annamycin-74d085c35cffa9c8Pharma Surgeen2026-08-03T12:46:33.000ZMoleculin Biotech Reports Positive Pivotal Phase 2/3 Trial Results for Annamycin in AMLhttps://www.pharmaradar360.com/article/aim-immunotech-announces-final-dose-in-phase-2-duripanc-trial-ahead-of-schedule-918caf39ddaf10e9Pharma Surgeen2026-08-03T12:44:00.000ZAIM ImmunoTech Announces Final Dose in Phase 2 DURIPANC Trial Ahead of Schedule for Ampligen in Metastatic Pancreatic Cancerhttps://www.pharmaradar360.com/article/veru-inc-announces-august-10-2026-conference-call-to-discuss-fiscal-third-quarte-272358e2f231c720Pharma Surgeen2026-08-03T12:44:00.000ZVeru Inc. Announces August 10, 2026 Conference Call to Discuss Fiscal Third Quarter Results and Business Updatehttps://www.pharmaradar360.com/article/cadrenal-therapeutics-solidifies-multi-indication-strategy-for-cad-1005-in-cardi-63ad04f5c7f9fb05Pharma Surgeen2026-08-03T12:42:36.000ZCadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuationhttps://www.pharmaradar360.com/article/veru-to-report-fiscal-2026-third-quarter-financial-results-on-august-10th-fbb23b37f096fab0Pharma Surgeen2026-08-03T12:42:22.000ZVeru to Report Fiscal 2026 Third Quarter Financial Results on August 10thhttps://www.pharmaradar360.com/article/novartis-pluvicto-leaps-ahead-into-earlier-manifestation-of-prostate-cancer-ddb68ca4eb8bd819Pharma Surgeen2026-08-03T12:33:04.000ZNovartis' Pluvicto leaps ahead into earlier manifestation of prostate cancerhttps://www.pharmaradar360.com/article/aim-immunotech-ahead-of-schedule-on-last-dose-duripanc-critical-clinical-inflect-7ba48c764ee7a95bPharma Surgeen2026-08-03T12:33:00.000ZAIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Pointhttps://www.pharmaradar360.com/article/krystal-biotech-releases-q2-2026-financial-results-1fcb8f05ce98ad36Pharma Surgeen2026-08-03T12:32:55.000ZKrystal Biotech Releases Q2 2026 Financial Resultshttps://www.pharmaradar360.com/article/china-biotech-giant-wuxi-apptec-sees-first-half-earnings-surge-amid-us-scrutiny-f26712cfbd4730e9Pharma Surgeen2026-08-03T12:30:14.000ZChina biotech giant WuXi AppTec sees first-half earnings surge amid US scrutinyhttps://www.pharmaradar360.com/article/intelligent-bio-solutions-drug-screen-tested-against-hand-creams-and-dirt-d040f2aebaf77fa3Pharma Surgeen2026-08-03T12:30:00.000ZIntelligent Bio Solutions drug screen tested against hand creams and dirthttps://www.pharmaradar360.com/article/cad-1005-phase-2-data-show-25-absolute-reduction-in-thrombotic-events-cba2478b70033c79Pharma Surgeen2026-08-03T12:30:00.000ZCAD-1005 Phase 2 Data Show >25% Absolute Reduction in Thrombotic Eventshttps://www.pharmaradar360.com/article/krystal-biotech-shares-slide-despite-earnings-beat-as-revenue-misses-forecasts-e45680fa9a05a567Pharma Surgeen2026-08-03T12:29:29.000ZKrystal Biotech Shares Slide Despite Earnings Beat as Revenue Misses Forecastshttps://www.pharmaradar360.com/article/085165079a02f176Pharma Surgeen2026-08-03T12:29:11.000ZΣυμπερίληψη Ελλάδας στον κατάλογο χωρών αναφοράς του Αιγυπτιακού Οργανισμού Φαρμάκων.https://www.pharmaradar360.com/article/altimmune-initiates-performa-phase-3-trial-of-pemvidutide-in-patients-with-mash-1f63f1f989ccc333Pharma Surgeen2026-08-03T12:20:58.000ZAltimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASHhttps://www.pharmaradar360.com/article/candel-therapeutics-to-present-extended-data-from-phase-3-results-of-aglatimagen-24afe6340484539dPharma Surgeen2026-08-03T12:05:00.000ZCandel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026https://www.pharmaradar360.com/article/acurx-s-550-patient-trial-could-support-c-diff-treatment-recurrence-reduction-b12dce6ba0ef4606Pharma Surgeen2026-08-03T12:00:00.000ZAcurx's ~550-Patient Trial Could Support C. diff Treatment, Recurrence Reductionhttps://www.pharmaradar360.com/article/which-is-the-better-state-street-healthcare-etf-the-broad-xlv-or-the-biotech-xbi-53858f6d9de117baPharma Surgeen2026-08-03T11:58:34.000ZWhich Is the Better State Street Healthcare ETF: The Broad XLV or the Biotech XBI?https://www.pharmaradar360.com/article/acv-keto-gummies-fda-approved-your-practical-guide-to-apple-cider-vinegar-supple-7f2b303f3e043432Pharma Surgeen2026-08-03T11:58:05.000ZACV Keto Gummies FDA Approved: Your Practical Guide to Apple Cider Vinegar Supplements *ePBM5upFp*https://www.pharmaradar360.com/article/fda-weight-loss-approved-drugs-evidence-based-options-for-safe-sustainable-resul-1ebff0dae5cf63cdPharma Surgeen2026-08-03T11:58:01.000ZFDA Weight Loss Approved Drugs: Evidence-Based Options for Safe, Sustainable Results *9RAcMCjbF*https://www.pharmaradar360.com/article/fda-proposes-restrictions-on-compounding-popular-weight-loss-medications-view-tf-e62684f02fa8f59fPharma Surgeen2026-08-03T11:56:46.000ZFDA Proposes Restrictions on Compounding Popular Weight Loss Medications - View tFixTzV5Qhttps://www.pharmaradar360.com/article/cordis-project-beyond-seasonal-suffering-effects-of-pollen-on-cardiorespiratory-0d29469987b3c76ePharma Surgeen2026-08-03T11:54:37.000ZCORDIS project: Beyond seasonal suffering: Effects of Pollen on Cardiorespiratory Health and Allergieshttps://www.pharmaradar360.com/article/cordis-project-european-health-data-and-evidence-network-62bd6cd17b37993ePharma Surgeen2026-08-03T11:54:37.000ZCORDIS project: European Health Data and Evidence Networkhttps://www.pharmaradar360.com/article/cordis-project-uncovering-the-epigenetic-signature-of-female-specific-biological-841e1eca0a7a44d4Pharma Surgeen2026-08-03T11:54:30.000ZCORDIS project: Uncovering the epigenetic signature of female-specifiC biological networks and key driver genes of coronary ArteRy diseasEhttps://www.pharmaradar360.com/article/cordis-project-from-pathobiology-to-synovia-on-chip-driving-rheumatoid-arthritis-14827fe35ff9fccaPharma Surgeen2026-08-03T11:54:04.000ZCORDIS project: From pathobioLogy to synoviA on chip: driving rheuMatoId arthritis to the precisioN medicine GOalhttps://www.pharmaradar360.com/article/cordis-project-a-european-cancer-image-platform-linked-to-biological-and-health-45b3193959b57389Pharma Surgeen2026-08-03T11:54:04.000ZCORDIS project: A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncologyhttps://www.pharmaradar360.com/article/fda-approved-weight-loss-patch-is-it-a-myth-or-a-realistic-option-view-wfolto9h9-08e21991723d5594Pharma Surgeen2026-08-03T11:53:54.000ZFDA Approved Weight Loss Patch: Is It a Myth or a Realistic Option? - View wfOLTo9h9https://www.pharmaradar360.com/article/cordis-project-risk-assessment-of-chemicals-integrating-human-centric-next-gener-0dc3bd15bed7742bPharma Surgeen2026-08-03T11:53:34.000ZCORDIS project: RISK assessment of chemicals integrating HUman centric Next generation Testing strategies promoting the 3Rshttps://www.pharmaradar360.com/article/us-biotech-firm-human-trials-for-covid-19-vaccine-could-be-held-in-israel-eaa46ab301853c65Pharma Surgeen2026-08-03T11:52:04.000ZUS biotech firm: Human trials for COVID-19 vaccine could be held in Israelhttps://www.pharmaradar360.com/article/who-launches-global-framework-to-decarbonise-pharma-sector-71e372a951aa5b83Pharma Surgeen2026-08-03T11:48:28.000ZWHO Launches Global Framework to Decarbonise Pharma Sectorhttps://www.pharmaradar360.com/article/helus-pharma-s-new-ceo-led-a-14-6b-sale-to-johnson-johnson-aebf7ab82766e1e8Pharma Surgeen2026-08-03T11:47:39.000ZHelus Pharma's New CEO Led a $14.6B Sale to Johnson & Johnsonhttps://www.pharmaradar360.com/article/lilly-s-olomorasib-receives-u-s-fda-s-breakthrough-therapy-designation-for-the-t-5795f7eaefe7a5d5Pharma Surgeen2026-08-03T11:45:00.000ZLilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancerhttps://www.pharmaradar360.com/article/zevra-therapeutics-announces-publication-of-four-year-real-world-data-from-u-s-e-8d04f4f7d91887ecPharma Surgeen2026-08-03T11:40:18.000ZZevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)https://www.pharmaradar360.com/article/krystal-biotech-stock-falls-7-on-revenue-miss-despite-earnings-beat-74cec4b4f86ab3afPharma Surgeen2026-08-03T11:40:00.000ZKrystal Biotech stock falls 7% on revenue miss despite earnings beathttps://www.pharmaradar360.com/article/bombay-hc-revokes-fda-suspension-of-navi-mumbai-hotel-considers-costs-over-delay-2b7d23ddbbb32343Pharma Surgeen2026-08-03T11:37:33.000ZBombay HC Revokes FDA Suspension Of Navi Mumbai Hotel, Considers Costs Over Delay Despite 100 Per Centhttps://www.pharmaradar360.com/article/biontech-appoints-guido-oelkers-as-new-chief-executive-officer-b0b578b67413c717Pharma Surgeen2026-08-03T11:34:50.000ZBioNTech appoints Guido Oelkers as new Chief Executive Officerhttps://www.pharmaradar360.com/article/earnings-call-transcript-concord-biotech-misses-q1-2026-estimates-fa7cfd88f3730f98Pharma Surgeen2026-08-03T11:25:53.000ZEarnings call transcript: Concord Biotech misses Q1 2026 estimateshttps://www.pharmaradar360.com/article/belite-bio-presents-updated-phase-3-data-on-oral-tinlarebant-for-stargardt-40efd445f854cd99Pharma Surgeen2026-08-03T11:24:06.000ZBelite Bio presents updated phase 3 data on oral tinlarebant for Stargardthttps://www.pharmaradar360.com/article/krystal-biotech-q2-net-income-product-revenue-rise-shares-down-pre-bell-ded21393db136993Pharma Surgeen2026-08-03T11:23:53.000ZKrystal Biotech Q2 Net Income, Product Revenue Rise; Shares Down Pre-Bellhttps://www.pharmaradar360.com/article/krystal-biotech-krys-q2-2026-earnings-810e347897bd0a77Pharma Surgeen2026-08-03T11:21:13.000ZKrystal Biotech (KRYS) Q2 2026 Earningshttps://www.pharmaradar360.com/article/ocular-therapeutix-reports-q2-2026-results-confirms-q4-2026-axpaxli-nda-submissi-aaa22de9efc013bdPharma Surgeen2026-08-03T11:15:00.000ZOcular Therapeutix Reports Q2 2026 Results, Confirms Q4 2026 AXPAXLI NDA Submission Plan for Wet AMDhttps://www.pharmaradar360.com/article/krystal-biotech-2q-2026-revenue-119-22m-eps-1-79-10-q-summary-7af38be3c21756ccPharma Surgeen2026-08-03T11:11:01.000ZKrystal Biotech 2Q 2026: Revenue $119.22M, EPS $1.79— 10-Q Summaryhttps://www.pharmaradar360.com/article/boletin-sobre-seguridad-de-medicamentos-de-uso-humano-junio-de-2026-56621e43adac5c9dPharma Surgeen2026-08-03T11:07:02.000ZBoletín sobre Seguridad de Medicamentos de Uso Humano. Junio de 2026https://www.pharmaradar360.com/article/krystal-biotech-q2-revenue-rises-to-119-2-million-on-vyjuvek-sales-9bef3aad3dc011afPharma Surgeen2026-08-03T11:06:00.000ZKrystal Biotech Q2 revenue rises to $119.2 million on VYJUVEK saleshttps://www.pharmaradar360.com/article/krystal-biotech-inc-quarterly-earnings-report-d7222c92b676b434Pharma Surgeen2026-08-03T11:03:59.000ZKrystal Biotech, Inc. Quarterly Earnings Reporthttps://www.pharmaradar360.com/article/cho-perfusion-model-lifts-yield-by-letting-cellular-waste-build-up-fe00ab79e494052cPharma Surgeen2026-08-03T11:00:41.000ZCHO perfusion model lifts yield by letting cellular waste build uphttps://www.pharmaradar360.com/article/opus-genetics-expects-data-in-2027-from-one-time-gene-therapy-trial-a62c779573496a38Pharma Surgeen2026-08-03T11:00:00.000ZOpus Genetics expects data in 2027 from one-time gene therapy trialhttps://www.pharmaradar360.com/article/opus-genetics-completes-patient-enrollment-in-b4b3490596318758Pharma Surgeen2026-08-03T11:00:00.000ZOpus Genetics Completes Patient Enrollment inhttps://www.pharmaradar360.com/article/what-would-it-take-to-get-peptides-on-the-shelf-26d4aa295f81e662Pharma Surgeen2026-08-03T11:00:00.000ZWhat would it take to get peptides on the shelf?https://www.pharmaradar360.com/article/fda-panel-ignites-debate-over-controversial-peptide-treatments-d1f587474973c5eaPharma Surgeen2026-08-03T11:00:00.000ZFDA Panel Ignites Debate Over Controversial Peptide Treatmentshttps://www.pharmaradar360.com/article/tg-therapeutics-reports-second-quarter-2026-financial-results-and-raises-briumvi-9725a783c2c7ad04Pharma Surgeen2026-08-03T11:00:00.000ZTG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidancehttps://www.pharmaradar360.com/article/can-fite-launches-first-clinical-program-for-piclidenoson-in-the-rare-genetic-di-42e44a139109431bPharma Surgeen2026-08-03T11:00:00.000ZCan-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndromehttps://www.pharmaradar360.com/article/safe-weight-loss-drugs-view-od49qcct3-1b45cf8583fd0d8cPharma Surgeen2026-08-03T10:55:34.000ZSafe Weight Loss Drugs - View oD49QcCT3https://www.pharmaradar360.com/article/over-the-counter-weight-loss-medication-what-works-what-doesn-t-and-how-to-pick-fc88611383fe20c0Pharma Surgeen2026-08-03T10:51:26.000ZOver the Counter Weight Loss Medication: What Works, What Doesn’t, and How to Pick a Safe Option in 2026 *0oSGFEEPg*https://www.pharmaradar360.com/article/online-platform-agrees-to-stop-selling-glp-1-drugs-to-us-customers-4ae3a90e731acbc0Pharma Surgeen2026-08-03T10:46:16.000ZOnline platform agrees to stop selling GLP-1 drugs to US customershttps://www.pharmaradar360.com/article/harbour-biomed-and-kelun-biotech-receive-china-ind-approval-for-bispecific-asthm-28a8e2cb4af12ff1Pharma Surgeen2026-08-03T10:41:15.000ZHarbour BioMed and Kelun-Biotech receive China IND approval for bispecific asthma therapyhttps://www.pharmaradar360.com/article/ipo-news-ipo-winners-losers-biotech-soars-jersey-mike-s-misses-and-spacex-faces-cb66f2714c114056Pharma Surgeen2026-08-03T10:27:59.000ZIPO News - IPO Winners & Losers: Biotech Soars, Jersey Mike's Misses, and SpaceX Faces the Lockuphttps://www.pharmaradar360.com/article/administrative-government-s-restrictions-on-mifepristone-are-arbitrary-and-capri-b00bb6a7d0696d7cPharma Surgeen2026-08-03T10:22:51.000ZAdministrative – Government’s restrictions on mifepristone are arbitrary and capricioushttps://www.pharmaradar360.com/article/retatrutide-weight-loss-jacksonville-view-hburryuvy-6cad9a61f3b39513Pharma Surgeen2026-08-03T10:20:10.000ZRetatrutide Weight Loss Jacksonville - View HburRYuVYhttps://www.pharmaradar360.com/article/partnership-to-create-ai-chemical-data-ecosystem-057e7a3c68334cd4Pharma Surgeen2026-08-03T10:18:40.000ZPartnership to create AI chemical data ecosystemhttps://www.pharmaradar360.com/article/fda-approved-weight-loss-patch-what-it-is-and-why-it-matters-or-doesn-t-view-rwf-ff263f0155237b91Pharma Surgeen2026-08-03T10:17:12.000ZFDA Approved Weight Loss Patch: What It Is and Why It Matters (or Doesn't) - View rwF6IMi5Zhttps://www.pharmaradar360.com/article/exec-on-execs-china-s-rise-in-biotech-investment-f29778c1aa52fb7fPharma Surgeen2026-08-03T10:12:56.000ZExec on Execs: China's Rise in Biotech Investmenthttps://www.pharmaradar360.com/article/116-100-shares-in-teva-pharmaceutical-industries-ltd-teva-bought-by-militia-capi-2cf0259463e000b9Pharma Surgeen2026-08-03T10:00:24.000Z116,100 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Bought by Militia Capital Management LLChttps://www.pharmaradar360.com/article/varda-announces-biopharma-leader-mikael-dolsten-will-join-board-as-space-based-p-e4fb549a68f2d79cPharma Surgeen2026-08-03T10:00:00.000ZVarda Announces Biopharma Leader Mikael Dolsten will Join Board as Space-Based Pharmaceutical Manufacturing Accelerateshttps://www.pharmaradar360.com/article/this-next-gen-glp-1-is-blowing-up-the-black-market-economy-789b37562a6bdc5aPharma Surgeen2026-08-03T10:00:00.000ZThis Next-Gen GLP-1 Is Blowing Up the Black Market Economyhttps://www.pharmaradar360.com/article/south-africa-prepares-for-potential-new-adult-tb-vaccine-13e0094d65226d45Pharma Surgeen2026-08-03T09:54:26.000ZSouth Africa Prepares for Potential New Adult TB Vaccinehttps://www.pharmaradar360.com/article/jeol-launches-two-high-resolution-microscopes-14fa5a388e190348Pharma Surgeen2026-08-03T09:48:03.000ZJeol launches two high-resolution microscopeshttps://www.pharmaradar360.com/article/radiopharm-asx-rad-expands-clinical-momentum-with-positive-trial-updates-80d2bdd2128ddf12Pharma Surgeen2026-08-03T09:47:00.000ZRadiopharm (ASX:RAD) Expands Clinical Momentum with Positive Trial Updateshttps://www.pharmaradar360.com/article/what-will-health-and-social-care-look-like-under-andy-burnham-dba84f191db4b195Pharma Surgeen2026-08-03T09:42:17.000ZWhat will health and social care look like under Andy Burnham?https://www.pharmaradar360.com/article/retatrutide-weight-loss-price-what-it-costs-in-2026-and-why-it-matters-view-9ujq-c30d07bade28054cPharma Surgeen2026-08-03T09:24:02.000ZRetatrutide Weight Loss Price: What It Costs in 2026 and Why It Matters - View 9UjQdSwbZhttps://www.pharmaradar360.com/article/pharmaceutical-weight-loss-view-bueibwgjg-819e94458d985951Pharma Surgeen2026-08-03T09:14:09.000ZPharmaceutical Weight Loss - View BUEiBWgjghttps://www.pharmaradar360.com/article/impact-licenses-ovarian-cancer-drug-senaparib-to-pharmanovia-cdc5924972d68a16Pharma Surgeen2026-08-03T09:00:51.000ZIMPACT licenses ovarian cancer drug senaparib to Pharmanoviahttps://www.pharmaradar360.com/article/fda-approved-weight-loss-medications-list-view-uyywmxlnc-c60d3939fe7ba1a4Pharma Surgeen2026-08-03T08:58:28.000ZFDA Approved Weight Loss Medications List - View UYywmxlnchttps://www.pharmaradar360.com/article/unlocking-peptide-permeability-with-high-throughput-sfc-epsa-analysis-eb2c8abc5f6e24c6Pharma Surgeen2026-08-03T08:54:43.000ZUnlocking peptide permeability with high-throughput SFC-EPSA analysishttps://www.pharmaradar360.com/article/breast-cancer-trial-highlights-promise-and-risks-of-dual-immunotherapy-61f474a8f3b39983Pharma Surgeen2026-08-03T08:54:24.000ZBreast Cancer Trial Highlights Promise and Risks of Dual Immunotherapyhttps://www.pharmaradar360.com/article/billionaire-stanley-druckenmiller-bought-this-biotech-stock-that-has-surged-400-3e0951d9f0d4c95fPharma Surgeen2026-08-03T08:52:00.000ZBillionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy?https://www.pharmaradar360.com/article/sven-borho-steps-down-from-worldwide-health-with-biotech-growth-s-hsu-becoming-c-cfa958a4e77a26b7Pharma Surgeen2026-08-03T08:48:04.000ZSven Borho steps down from Worldwide Health with Biotech Growth's Hsu becoming co-managerhttps://www.pharmaradar360.com/article/astrazeneca-and-bms-in-talks-over-major-pharmaceutical-merger-9bba81a2f5976adePharma Surgeen2026-08-03T08:47:52.000ZAstraZeneca And BMS In Talks Over Major Pharmaceutical Mergerhttps://www.pharmaradar360.com/article/regulatory-round-up-3-august-2026-317fac41e47f8f05Pharma Surgeen2026-08-03T08:45:47.000ZRegulatory round-up: 3 August 2026https://www.pharmaradar360.com/article/ractigen-wins-fda-ind-clearance-for-sarna-candidate-507244f35c63b056Pharma Surgeen2026-08-03T08:36:25.000ZRactigen wins FDA IND clearance for saRNA candidatehttps://www.pharmaradar360.com/article/astrazeneca-in-talks-to-create-300bn-pharmaceutical-giant-f730c2e4f3a0c6bePharma Surgeen2026-08-03T08:36:00.000ZAstraZeneca ‘in talks to create £300bn pharmaceutical giant’https://www.pharmaradar360.com/article/dongkook-pharm-nears-w1-trillion-sales-milestone-83545cfd7cd251cbPharma Surgeen2026-08-03T08:30:43.000ZDongkook Pharm Nears W1 Trillion Sales Milestonehttps://www.pharmaradar360.com/article/pneumococcal-polysaccharide-conjugate-vaccine-pcv20-pgd-template-e123e687bede1c8dPharma Surgeen2026-08-03T08:30:00.000ZPneumococcal polysaccharide conjugate vaccine (PCV20) PGD templatehttps://www.pharmaradar360.com/article/pcv-13-valent-or-15-valent-adsorbed-patient-group-direction-pgd-template-9f8a91512dbcc4ffPharma Surgeen2026-08-03T08:30:00.000ZPCV (13-valent or 15-valent, adsorbed): patient group direction (PGD) templatehttps://www.pharmaradar360.com/article/dhsc-privacy-notice-6199fbf5d25ab84cPharma Surgeen2026-08-03T08:30:00.000ZDHSC privacy noticehttps://www.pharmaradar360.com/article/department-of-health-and-social-care-record-of-processing-activity-ropa-0a8251143f475789Pharma Surgeen2026-08-03T08:30:00.000ZDepartment of Health and Social Care record of processing activity (RoPA)https://www.pharmaradar360.com/article/bcg-vaccine-ajv-patient-group-direction-pgd-template-d5eac209b6d2a75cPharma Surgeen2026-08-03T08:30:00.000ZBCG Vaccine AJV: patient group direction (PGD) templatehttps://www.pharmaradar360.com/article/billionaire-stanley-druckenmiller-bought-this-biotech-stock-that-has-surged-400-dcbf1871be4923ebPharma Surgeen2026-08-03T08:28:12.000ZBillionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy?